Importantly, 1-MT-induced inhibition of IDO1 activity in TLR-2-primed WTDCs (WTDCsPam3CSK4+1-MT) completely abrogated their capacity to attenuate CDDP-induced AKI in CDDP-treated WT (WTWTDCsPam3CSK4+1-MT; Figure 8) and Gal-3-/-(Gal-3-/-WTDCsPam3CSK4+1-MT; Figure 9) recipients. This evidence concerns the gene TLR2 and acute kidney injury.